ArticleMolecular biology reports2025
Combined supplementation of leucine and glutamine acts as a novel therapeutic approach to alleviate hyperglycemia and oxidative stress by targeting insulin signalling genes in a drosophila model of type 2 diabetes.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo evaluate the therapeutic potential of leucine and glutamine, individually and in combination, in alleviating metabolic dysfunction associated with Type 2 Diabetes (T2D) using a high sucrose diet-induced Drosophila model of T2D.
methodsT2D was induced in flies by feeding a high-sucrose diet (35%). Optimal nontoxic doses of leucine and glutamine were administered to T2D flies for seven days. The therapeutic effects were assessed in individual and combined doses through biochemical, histological, and molecular analyses.
resultsCombined leucine and glutamine supplementation demonstrated superior efficacy over individual treatments. Biochemical analysis revealed that supplementation alleviates hyperglycemia and hyperlipidemia. Improved oxidative stress markers are indicated by increased thiol levels, DPPH radical scavenging, antioxidant enzyme activity, decreased protein carbonylation, and lipid peroxidation. Histological assessment found less lipid droplet accumulation in the gut, reduced reactive oxygen species accumulation, restoration of actin filament architecture, and decreased apoptotic cell death in the gut and malpighian tubules. Efflux activity in malpighian tubules was significantly improved post-treatment. qPCR studies indicate that the combination therapy of Leucine and Glutamine predominantly targets downstream components of insulin signaling pathways, including chico and Akt, while secondarily stimulating insulin secretion, which typically diminishes in the later stages of chronic hyperglycemia. The elevation of cytoskeletal genes Actin 57B and Actin 88 F and elevated mRNA expression of sns and kirre, essential for nephrocyte-mediated hemolymph detoxification, underscores the multifaceted treatment strategy.
conclusionThe current study underscores the potential of leucine and glutamine co-supplementation as a promising intervention to mitigate metabolic dysregulation in T2D.
Indexed as
Identifiers
41136643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.